Answers are grounded in this paper and cite their sources.
We reported a clinical case of an 84-year-old smoker who was diagnosed with stage IV lung cancer and was included in the phase III clinical trial and treated with racotumomab. The patient had a an ECOG grade 0 according to the function scale. Therefore, it should be emphasized that this vaccine can improve the survival rate of patients with recurrent or advanced non-small cell lung cancer.
No takes yet. Share an insight, caveat, or question.
Casola et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: